Chinese scientists have discovered that a migraine medication is expected to aid in the immunotherapy of triple-negative breast cancer

The Breast Tumor Center of Fudan University Affiliated Tumor Hospital, in collaboration with the research team of the Fudan University Institute of Translational Neuroscience, discovered that sensory nerves in tumors are the "culprit" causing some triple-negative breast cancer patients to develop resistance to immunotherapy in the short term, and found that a drug used to treat migraines can enhance the sensitivity to immunotherapy. The related results were published on the 6th in the international academic journal "Cell." (Xinhua News Agency)